VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced preliminary financial results from the third quarter
ended September 30, 2007 and updated its financial outlook for the
full year ending December 31, 2007, in conjunction with the release
of Boston Scientific Corporation's (BSC) third quarter financial
results earlier today. Angiotech will release its complete third
quarter financial results, including Management's Discussion and
Analysis of Financial Condition and Results of Operations, and hold
its third quarter results conference call for analysts and
investors, as scheduled on November 1, 2007. Selected preliminary
unaudited financial results for the third quarter are as follows: -
Total revenues were $68.0 million. - Net product sales were $41.4
million and were derived primarily from sales of our various
single-use specialty medical devices as well as from sales of
medical device components to third parties. - Royalty revenue was
$26.6 million and included $24.9 million of royalty revenue derived
from sales by BSC of paclitaxel-eluting coronary stent systems. -
Adjusted EBITDA (earnings before interest, taxes, depreciation and
amortization, adjusted to exclude certain non-cash and
non-recurring items) was $7.2 million. Excluding research and
development expenses, the significant majority of which are
discretionary and relate primarily to our Pharmaceutical
Technologies segment, Adjusted EBITDA would be $19.8 million. -
Cash and long-term investments were $132.7 million. - Angiotech
expects to post a net loss on a GAAP and adjusted basis for the
third quarter, pending finalization of certain tax items. With the
third quarter results as reported, we are updating our full year
2007 outlook as follows: - We are updating our full year 2007
expected royalty revenue range to $118 million to $120 million,
based on third quarter paclitaxel- eluting stent sales of $448
million announced by BSC in its third quarter earnings release
earlier today and from which we will derive and record royalty
revenue in our fourth quarter of 2007. BSC announced on October 16
that it plans to present a broad range of clinical trial data
reinforcing the safety and efficacy of TAXUS(R) coronary stent
systems at the upcoming Transcatheter Cardiovascular Therapeutics
(TCT 2007) scientific symposium, which runs from October 20 to 25
in Washington, DC. - We are revising our 2007 medical product sales
outlook to a range of $171 million to $173 million, from our
previous range of $190 million to $210 million. Our previous range
included expected revenue of $180 million to $190 million from
medical products obtained in the acquisition of American Medical
Instruments, Inc. (AMI) and $10 million to $30 million from new
product lines. We expect fourth quarter net medical product sales
to be between $42 million and $44 million. - Our full year 2007
outlook for revenue derived from sales of medical products obtained
from AMI is modestly lower as compared to our original expectations
as a result of our decision to de-emphasize or discontinue certain
product lines that were generating limited or negative contribution
margins in the second half of 2007. In addition, our previously
announced decision to consolidate certain operations and close our
facility in Syracuse, NY has impacted the shipment and production
timing of a limited number of orders for surgical needles. - Our
original full year 2007 outlook for sales revenue derived from
certain new product lines was $10 million to $30 million. At the
present time we expect to begin generating more substantial revenue
from these sources starting in 2008, rather than in the second half
of 2007 as originally expected, as a result of several factors,
including: - Longer regulatory review times than originally
expected, primarily for our Vascular Wrap(TM) product candidate in
the European Union (EU). While we completed our EU clinical trial
and submitted all regulatory filings as planned, review and
approval timelines are entirely at the discretion of the regulatory
body in the EU, and are not specifically mandated. We had
originally expected this product candidate would be approved for
sale by the third quarter of 2007. We now expect this product
candidate, should it receive EU regulatory approval, to be
available for sale in first half of 2008; - An initial "time to
first order" of 9 to 12 months, as opposed to the originally
forecasted 3 to 6 months, for our Quill(TM) SRS product line in the
majority of customer accounts. Importantly, we continue to remain
on track to sign up approximately 275 customer accounts by
year-end. As of October 2007, we had signed approximately 230
Quill(TM) SRS customer accounts, including 67 hospitals, 89 clinics
and 74 physician offices, as compared to only a small number of
ordering accounts and fewer than 10 hospitals as of June 2007. As a
result of positive physician reception for the Quill(TM) SRS
product launch, we have accelerated our investments in sales and
marketing, completed our hiring plans ahead of our original
schedule, and will continue to invest research and development
resources to expand the Quill(TM) SRS product line, with the goal
of offering approximately 40 Quill(TM) SRS SKUs by year-end. - Our
full year 2007 outlook for certain expenses, including selling,
general and administrative and research and development expenses,
remains consistent with ranges as previously communicated, with
increases in sales and marketing related expenses as compared to
the upper end of the range a possibility. This outlook is inclusive
of investments in the second half of 2007 relating to: - Sales
force expansion, product launch and market development initiatives
for Quill(TM) SRS and our interventional business; - Launch
preparation activities related to our HemoStream(TM) dialysis
catheter product line, which recently received regulatory approval
one quarter in advance of our original expectations; - The
acceleration of clinical trial activities relating to our Vascular
Wrap(TM) product candidate in the U.S.; - EU product launch and
U.S. clinical trial activities relating to our Bio-Seal(TM) lung
biopsy product line. - As a result of the revenue delays and the
decision to maintain investment in critical programs, we are
updating our full year 2007 Adjusted EBITDA outlook range to $47
million to $50 million from the previously stated $85 million to
$95 million. Excluding research and development expenses, the
significant majority of which are discretionary and relate
primarily to our Pharmaceutical Technologies segment, our expected
Adjusted EBITDA range would be $99 million to $102 million. - Our
outlook regarding adjusted net income per share for 2007 will be
updated on November 1, 2007, pending finalization of certain tax
items. We caution that the information above concerning our revised
outlook for 2007 is forward-looking and accordingly, actual results
may differ materially. "We remain optimistic about our numerous new
product opportunities and the revenue potential they provide for
Angiotech. Physician excitement for Quill(TM) SRS and other new
Angiotech products, our recent positive clinical trial results for
our 5-FU CVC product candidate, and the continued progress of our
various research and product development programs give us
confidence that we should see improved product revenue growth in
2008," said Dr. William Hunter, President and CEO of Angiotech.
"While we had hoped to achieve higher revenues and adjusted EBITDA
in the third and fourth quarters of 2007 - the largest impact
coming from the delayed timing of revenue from newly launched
products - we anticipate that our various businesses and
investments in sales, marketing and medical research will deliver
growth in 2008," said Thomas Bailey, Chief Financial Officer of
Angiotech. Upcoming Third Quarter Conference Call Information A
conference call to discuss these financial results will be held on
Thursday, November 1, 2007 at 8:00 AM PT (11:00 AM ET). Dial-in
information: North America (toll free): (800) 901-5213
International: (617) 786-2962 Enter passcode: 75137732 A replay
archive of the conference call will be available until November 8,
2007 by calling (888) 286-8010 (in North America) or (617) 801-6888
(International) and entering Passcode 15190735. A live webcast will
be available to all interested parties through Angiotech's website
at http://www.angiotech.com/ in the Investor Relations section.
Financial Information and Certain Non-GAAP Financial Measures
Amounts, unless specified otherwise, are expressed in U.S. dollars.
Financial results are reported under GAAP unless otherwise noted.
All per share amounts are stated on a diluted basis unless
otherwise noted. This press release contains preliminary unaudited
financial results for the three month period ended and as of
September 30, 2007. Because the selected financial results
described in this release are preliminary, these results remain
subject to change to reflect necessary corrections or adjustments
or changes in accounting estimates that are identified prior to the
time that we release our complete third quarter results. Actual
results may vary from the results presented in this release. We
will release our complete third quarter financial results,
including Management's Discussion and Analysis of Financial
Condition and Results of Operations, and hold our third quarter
results conference call for analysts and investors, as scheduled on
November 1, 2007. Certain financial results presented in this press
release include non-GAAP measures that exclude certain items.
Adjusted net income from continuing operations, adjusted net income
per share from continuing operations and adjusted earnings before
interest, taxes, depreciation and amortization ("Adjusted EBITDA")
exclude acquisition related amortization charges, acquired
in-process research and development relating to license agreements
and acquisitions, stock-based compensation expense, foreign
exchange gains or losses relating to translation of foreign
currency cash and investment balances and other non-recurring
items. Adjusted net income from continuing operations, adjusted net
income per share from continuing operations and Adjusted EBITDA
also exclude litigation expenses related to defending intellectual
property claims. Adjusted net income from continuing operations,
adjusted net income per share from continuing operations, and
Adjusted EBITDA do not have any standardized meaning prescribed by
GAAP and therefore may not be comparable to similar measures
presented by other issuers. Management uses certain non-GAAP or
adjusted operating measures to establish operational goals and
assess corporate performance, and believes that these measures may
assist investors in analyzing the underlying trends in our business
over time. Investors should consider this non-GAAP measure in
addition to, not as a substitute for, or as superior to, financial
reporting measures prepared in accordance with GAAP. The financial
outlook in this press release presents certain forward-looking,
non-GAAP financial information for which at this time there is no
calculable comparable GAAP measure or which at this time cannot be
quantitatively reconciled to GAAP financial information.
Specifically, reconciliation of our EBITDA and Adjusted EBITDA
outlook to GAAP-based financial information is not feasible at this
time, as it would require the estimation of certain expenses that
are inherently unpredictable or subject to significant fluctuation
for reasons unrelated to our underlying business performance,
including stock-based compensation expenses, litigation expenses
and foreign exchange gains or losses. Note on Forward Looking
Statements Statements contained in this press release that are not
based on historical fact, including without limitation statements
containing the words "believes," "may," "plans," "will,"
"estimate," "continue," "anticipates," "intends," "expects" and
similar expressions, constitute "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995 and constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. All such statements
are made pursuant to the "safe harbor" provisions of applicable
securities legislation. Forward-looking statements may involve, but
are not limited to, comments with respect to our strategies or
future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations,
research development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among
others, the following: general economic and business conditions,
both nationally and in the regions in which we operate; market
demand; technological changes that could impact our existing
products or our ability to develop and commercialize future
products; competition; existing governmental regulations and
changes in, or the failure to comply with, governmental
regulations; adverse results or unexpected delays in drug discovery
and clinical development processes; decisions, and the timing of
decisions, made by health regulatory agencies regarding approval of
our technology and products; the requirement for substantial
funding to conduct research and development and to expand
commercialization activities or consummate acquisitions; sales
numbers and future guidance publicly provided by Boston Scientific
Corporation regarding sales of their paclitaxel-eluting coronary
stent products; and any other factors that may affect performance.
In addition, our business is subject to certain operating risks
that may cause the actual results expressed or implied by the
forward-looking statements in this report to differ materially from
our actual results. These operating risks include: our ability to
attract and retain qualified personnel; our ability to successfully
complete preclinical and clinical development of our products;
changes in business strategy or development plans; our failure to
obtain patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston
Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued
availability of capital to finance our activities; our ability to
continue to integrate into our business the operations of American
Medical Instruments Holdings, Inc. ("AMI"); our ability to achieve
the operational and other synergies and the other commercial or
financial benefits expected as a result of the acquisition of AMI;
and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or
developments. TAXUS(R) is a registered trademark of Boston
Scientific Corporation. Quill(TM) is a trademark of Quill Medical,
Inc., a wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc.
Vascular Wrap(TM) is a trademark of Angiotech Pharmaceuticals, Inc.
HemoStream(TM) is a trademark of Rex Medical, LP, used under
license by Angiotech. About Angiotech Angiotech Pharmaceuticals,
Inc. is a global specialty pharmaceutical and medical device
company with over 1,500 dedicated employees. Angiotech discovers,
develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. ANGIOTECH PHARMACEUTICALS, INC.
CALCULATION OF ADJUSTED EBITDA (Unaudited) Three months ended (in
thousands of U.S.$) September 30, 2007
-------------------------------------------------------------------------
Loss from continuing operations before income taxes on a GAAP basis
(17,072) Interest expense on long-term debt 13,281 Depreciation and
amortization from continuing operations 9,153
-------------------------------------------------------------------------
EBITDA from continuing operations 5,362
-------------------------------------------------------------------------
Adjustments: Non-recurring revenue, net of license fees (54)
Stock-based compensation 1,353 Litigation expenses 908 Foreign
exchange gain (41) Investment and other income (2,072)
Severance/restructuring costs 1,454 E&O inventory adjustment
253
-------------------------------------------------------------------------
Adjusted EBITDA 7,163
-------------------------------------------------------------------------
-------------------------------------------------------------------------
CONTACT: Media: Jodi Regts, Senior Manager, Corporate
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, ;
Analyst and Investors: Deirdre Neary, Manager, Investor Relations,
Angiotech Pharmaceuticals, Inc., (604) 222-7056, DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: Media: Jodi Regts, Senior
Manager, Corporate Communications, Angiotech Pharmaceuticals, Inc.,
(604) 221-7930, ; Analyst and Investors: Deirdre Neary, Manager,
Investor Relations, Angiotech Pharmaceuticals, Inc., (604)
222-7056,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024